Oral-parenteral conversion factor for morphine in palliative cancer care: A prospective randomized crossover pilot study

Pain Research and Treatment

Volumn 2011, Issue , 2011, Pages

  Starlander, Jan ^a   Melin Johansson, Christina ^b   Jonsson, Håkan ^c   Axelsson, Bertil ^a,d,e  

^a ÖSTERSUND HOSPITAL   (Sweden)

^b MID SWEDEN UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d Research and Development Unit   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873850871     PISSN: 20901542     EISSN: 20901550     Source Type: Journal    
DOI: 10.1155/2011/504034     Document Type: Article

References (15)

1. WHO, Cancer Pain Relief: With a Guide to Opioid Availability 1996 Geneva, Switzerland WHO
2. Hanks G. W., Conno F. D., Cherny N., Hanna M., Kalso E., McQuay H. J., Mercadante S., Meynadier J., Poulain P., Ripamonti C., Radbruch L., Casas J. R. I., Sawe J., Twycross R. G., Ventafridda V., Morphine and alternative opioids in cancer pain: the EAPC recommendations. British Journal of Cancer 2001 84 5 587 593 2-s2.0-0037758126 10.1054/bjoc.2001.1680 (Pubitemid 32238990)
3. Gourlay G. K., Treatment of cancer pain with transdermal fentanyl. The Lancet Oncology 2001 2 3 165 172 2-s2.0-0035295968 10.1016/S1470-2045(00)00258-8 (Pubitemid 33585928)
4. Jeal W., Benfield P., Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997 53 1 109 138 2-s2.0-0031018574 (Pubitemid 27042235)
5. Glare P. A., Walsh T. D., Clinical pharmacokinetics of morphine. Therapeutic Drug Monitoring 1991 13 1 1 23 2-s2.0-0026090264
6. Lasheen W., Walsh D., Mahmoud F., Sarhill N., Rivera N., Davis M., Lagman R., Legrand S., The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain. Palliative Medicine 2010 24 1 9 16 2-s2.0-75149192577 10.1177/0269216309346595
7. Takahashi M., Ohara T., Yamanaka H., Shimada A., Nakaho T., Yamamuro M., The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment. Palliative Medicine 2003 17 8 673 678 2-s2.0-0345099462 (Pubitemid 37508951)
8. Zubrod C. G., Scheiderman M., Frei E., Cancer-Appraisal of methods for the study of chemotherapy of cancer in man: thiophosphamide. Journal of Chronic Disease 1960 11 7 33
9. Mercadant S., The role of morphine glucuronides in cancer pain. Palliative Medicine 1999 13 2 95 104 2-s2.0-0032939615 10.1191/ 026921699678158579 (Pubitemid 29171390)
10. Wolff T., Samuelsson H., Hedner T., Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain 1995 62 2 147 154 2-s2.0-0029129171 10.1016/0304-3959(94)00268-J
11. Nelson K. A., Glare P. A., Walsh D., Groh E. S., A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. Journal of Pain and Symptom Management 1997 13 5 262 267 2-s2.0-0031004862 10.1016/S0885-3924(96)00329-6 (Pubitemid 27240679)
12. Faura C. C., Moore R. A., Horga J. F., Hand C. W., McQuay H. J., Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. Journal of Pain and Symptom Management 1996 11 2 95 102 2-s2.0-0029917062 10.1016/0885-3924(95)00148-4 (Pubitemid 26073495)
13. Klepstad P., Kaasa S., Borchgrevink P. C., Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. European Journal of Clinical Pharmacology 2000 55 10 713 719 2-s2.0-0033984820 (Pubitemid 30077565)
14. Quigley C., Joel S., Patel N., Baksh A., Slevin M., Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliative Medicine 2003 17 2 185 190 2-s2.0-0037251596 10.1191/0269216303pm658oa (Pubitemid 36432596)
15. Klepstad P., Hilton P., Moen J., Kaasa S., Borchgrevink P. C., Zahlsen K., Dale O., Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study. BMC Clinical Pharmacology 2004 4, article 7 2-s2.0-13244269855 10.1186/1472-6904-4-7 (Pubitemid 40195480)